Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
F 11.70 -2.58% -0.31
SAGE closed down 2.58 percent on Friday, May 17, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -2.58%
New 52 Week Closing Low Bearish -0.09%
Gapped Up Strength -0.09%
Oversold Stochastic Weakness -0.09%
Gapped Up Strength -2.42%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sage Therapeutics, Inc. Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Clinical Development Pharmacology Central Nervous System Disorders Nervous System Disorders Toxicology Seizure Antidepressants Gabaa Receptor Positive Allosteric Modulators Adjunctive Therapy Anticonvulsants Neurosteroids Status Epilepticus

Is SAGE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.98
52 Week Low 10.92
Average Volume 1,037,424
200-Day Moving Average 20.08
50-Day Moving Average 15.83
20-Day Moving Average 12.90
10-Day Moving Average 12.24
Average True Range 0.84
RSI (14) 31.97
ADX 35.35
+DI 16.21
-DI 28.18
Chandelier Exit (Long, 3 ATRs) 12.46
Chandelier Exit (Short, 3 ATRs) 13.98
Upper Bollinger Bands 14.51
Lower Bollinger Band 11.29
Percent B (%b) 0.13
BandWidth 25.01
MACD Line -1.13
MACD Signal Line -1.21
MACD Histogram 0.0731
Fundamentals Value
Market Cap 703.25 Million
Num Shares 60.1 Million
EPS -10.98
Price-to-Earnings (P/E) Ratio -1.07
Price-to-Sales 124.79
Price-to-Book 1.74
PEG Ratio 0.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.26
Resistance 3 (R3) 12.31 12.17 12.16
Resistance 2 (R2) 12.17 12.03 12.15 12.13
Resistance 1 (R1) 11.94 11.94 11.87 11.89 12.10
Pivot Point 11.80 11.80 11.77 11.78 11.80
Support 1 (S1) 11.57 11.66 11.50 11.52 11.30
Support 2 (S2) 11.43 11.57 11.41 11.27
Support 3 (S3) 11.20 11.43 11.24
Support 4 (S4) 11.15